Latest News and Press Releases

Curevo Vaccine closes a $110 million Series B round led by Medicxi, with new investors OrbiMed, HBM Healthcare Investments, and Sanofi Ventures.

Updated Phase 2 data one year after the second vaccine dose, the anti-gE antibody immune response to amezosvatein continues to be non-inferior to Shingrix

Curevo Vaccine will present at the 2025 JPM Healthcare Conference on Wednesday January 15th.

Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit vaccine

Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein elicits robust immune responses with better tolerability.

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus vaccines with improved...

-- Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein met the primary immunogenicity endpoint, eliciting a robust immune response non-inferior to Shingrix, including...

SEATTLE, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe...

SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe...